CASI Pharmaceuticals Crescita futura

Future criteri di controllo 2/6

Si prevede che CASI Pharmaceuticals aumenterà gli utili e i ricavi rispettivamente del 9% e 35.9% all'anno, mentre si prevede che l'EPS crescerà del 12.9% all'anno.

Informazioni chiave

9.0%

Tasso di crescita degli utili

12.9%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	27.6%
Tasso di crescita dei ricavi	35.9%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	15 May 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

The Market Doesn't Like What It Sees From CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Revenues Yet As Shares Tumble 34%

Nov 26

CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

May 21

Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%

Mar 12

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%

Dec 18

Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?

May 26

Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts

Aug 14

Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?

May 25

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:CASI - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	70	-28	N/A	N/A	1
12/31/2025	46	-33	N/A	N/A	1
12/31/2024	20	-36	N/A	N/A	1
9/30/2024	22	-31	N/A	N/A	N/A
6/30/2024	23	-27	N/A	N/A	N/A
3/31/2024	29	-30	N/A	N/A	N/A
12/31/2023	34	-27	-22	-20	N/A
9/30/2023	42	-40	N/A	N/A	N/A
6/30/2023	44	-41	N/A	N/A	N/A
3/31/2023	42	-38	N/A	N/A	N/A
12/31/2022	43	-41	-27	-21	N/A
9/30/2022	37	-27	-35	-28	N/A
6/30/2022	35	-32	-35	-25	N/A
3/31/2022	33	-31	-34	-23	N/A
12/31/2021	30	-37	-42	-27	N/A
9/30/2021	26	-45	-44	-27	N/A
6/30/2021	22	-52	-54	-30	N/A
3/31/2021	17	-54	-53	-29	N/A
12/31/2020	15	-48	-43	-26	N/A
9/30/2020	12	-47	-41	-23	N/A
6/30/2020	10	-40	-29	-21	N/A
3/31/2020	8	-46	-36	-23	N/A
12/31/2019	4	-46	-37	-23	N/A
9/30/2019	3	-43	-42	-34	N/A
6/30/2019	N/A	-42	-42	-33	N/A
3/31/2019	N/A	-32	-31	-28	N/A
12/31/2018	N/A	-27	-50	-29	N/A
9/30/2018	N/A	-23	-35	-15	N/A
6/30/2018	N/A	-16	N/A	-12	N/A
3/31/2018	N/A	-13	N/A	-11	N/A
12/31/2017	N/A	-11	N/A	-6	N/A
9/30/2017	N/A	-8	N/A	-7	N/A
6/30/2017	N/A	-8	N/A	-7	N/A
3/31/2017	N/A	-9	N/A	-6	N/A
12/31/2016	N/A	-9	N/A	-6	N/A
9/30/2016	N/A	-8	N/A	-6	N/A
6/30/2016	N/A	-8	N/A	-6	N/A
3/31/2016	0	-7	N/A	-6	N/A
12/31/2015	0	-7	N/A	-6	N/A
9/30/2015	0	-7	N/A	-5	N/A
6/30/2015	0	-27	N/A	-5	N/A
3/31/2015	0	-27	N/A	-4	N/A
12/31/2014	0	-26	N/A	-4	N/A
9/30/2014	N/A	-26	N/A	-4	N/A
6/30/2014	N/A	-6	N/A	-4	N/A
3/31/2014	N/A	-6	N/A	-4	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che CASI rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che CASI rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che CASI rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di CASI ( 35.9% all'anno) crescerà più rapidamente del mercato US ( 9.1% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di CASI ( 35.9% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di CASI è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2024/12/23 17:14
Prezzo dell'azione a fine giornata	2024/12/23 00:00
Guadagni	2024/09/30
Guadagni annuali	2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

^* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .

Fonti analitiche

CASI Pharmaceuticals, Inc. è coperta da 8 analisti. 1 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Justin Zelin	BTIG
Nathaniel Calloway	Edison Investment Research
Ching-Yi Lin	H.C. Wainwright & Co.

CASI Pharmaceuticals Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus revenue estimates fall by 67%

No longer forecast to breakeven

Forecast to breakeven in 2024

Consensus EPS estimates upgraded to US$1.88 loss, revenue downgraded

Consensus forecasts updated

Forecast to breakeven in 2024

Recent updates

The Market Doesn't Like What It Sees From CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Revenues Yet As Shares Tumble 34%

New minor risk - Share price stability

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

CASI Pharmaceuticals, Inc. Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia

CASI Pharmaceuticals, Inc. Announces Change of Senior Management Positions

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Shareholder dilution

CASI Pharmaceuticals, Inc. Appoints Daniel Lang as CFO

CASI Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding from VR Adviser, LLC, Foresite Capital Management, LLC, Panacea Venture Management Co., Ltd.

CASI Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Consensus revenue estimates fall by 67%

CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

First quarter 2024 earnings: EPS and revenues miss analyst expectations

No longer forecast to breakeven

CASI Pharmaceuticals Receives FDA Clearance on the Investigational New Drug (IND) Application for CID-103 in Immune Thrombocytopenia

New minor risk - Profitability

CASI Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 20, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%

CASI Pharmaceuticals Report Positive Interim Phase 1 Data for BI-1206 in the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma in China

CASI Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 20, 2024

Casi Pharmaceuticals Announces First Dose of Folotyn in China

CASI Pharmaceuticals, Inc. Announces Resignation of Fuqiang Zhang as Chief Commercial Officer

CASI Pharmaceuticals, Inc. Appoints of Mr. Huang Hai as the Global Chief Commercial Officer

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast to breakeven in 2024

We're Keeping An Eye On CASI Pharmaceuticals' (NASDAQ:CASI) Cash Burn Rate

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

CASI Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 01, 2023

CASI Pharmaceuticals, Inc.(NasdaqCM:CASI) dropped from S&P TMI Index

Consensus EPS estimates upgraded to US$1.88 loss, revenue downgraded

Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

CASI Pharmaceuticals, Inc. Announces Clinical Trial Application Approval for CB-5339 in Patients with Multiple Myeloma in China

Consensus forecasts updated

Forecast to breakeven in 2024

Price target decreased to US$18.33

Insufficient new directors

Casi to sell stake in Juventas to Jiadao Gongcheng for ~RMB240.87M

CASI Pharmaceuticals and BioInvent Announces Dosing of First Patient in BI-1206 Phase 1 Clinical Trial for the Treatment of Relapsed/Refractory Non-Hodgkin's Lymphoma in China

Consensus forecasts updated

Price target decreased to US$22.67

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

CASI Pharmaceuticals Q2 2022 Earnings Preview

CASI Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 12, 2022

Chairman & CEO recently bought US$273k worth of stock

Price target decreased to US$37.00

Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?

No longer forecast to breakeven

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

CASI Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target increased to US$4.67

Insufficient new directors

CASI Pharmaceuticals, Inc., Annual General Meeting, May 25, 2022

Consensus forecasts updated

Full year 2021 earnings: EPS misses analyst expectations

Price target increased to US$4.67

CASI Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2022

CASI Pharmaceuticals Receives Nasdaq Deficiency Notice

Forecast to breakeven in 2024

CASI Pharmaceuticals, Inc. (NasdaqCM:CASI) announces an Equity Buyback for $10 million worth of its shares.

Casi Pharmaceuticals and Bioinvent Announce CTA Approval for Clinical Study of Bi-1206 in NHL in China

Chairman & CEO recently bought US$394k worth of stock

Third quarter 2021 earnings released: US$0.073 loss per share (vs US$0.14 loss in 3Q 2020)

Chairman & CEO recently bought US$614k worth of stock

Second quarter 2021 earnings released: US$0.05 loss per share (vs US$0.086 loss in 2Q 2020)

Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts